Market Place
Sourcing Support
All News #Library
Biotech
Aavantgarde To Present New LUCE Ph 1/2 Data At ARVO 2026
23 Apr 2026 //
GLOBENEWSWIRE
AAVantgarde Completes LUCE-1 Ph 1/2 Trial Enrollment for AAVB-081
15 Jan 2026 //
GLOBENEWSWIRE
AAVantgarde To Present At 44th J.P. Morgan Healthcare Conference
08 Jan 2026 //
GLOBENEWSWIRE
Italian Biotech Raises $141M Series B To Fund Eye Gene Therapies
04 Nov 2025 //
FIERCE BIOTECH
Aavantgarde Reveals 3 Presentations At ESGCT 2025 Conference
07 Oct 2025 //
GLOBENEWSWIRE
AAVantgarde Reports Positive AAVB-081 Data for Usher 1B
05 Sep 2025 //
GLOBENEWSWIRE
Aavantgarde to Unveil LUCE-1 Study Clinical Data at EURetina 2025
28 Aug 2025 //
GLOBENEWSWIRE
AAVantgarde Gets FDA Nod for Asset AAVB-039 Phase 1/2 Trial
15 Jul 2025 //
GLOBENEWSWIRE
AAVantgarde Shares Usher 1B, Stargardt Trial Updates
12 May 2025 //
GLOBENEWSWIRE
AAVantgarde names Rasmus Holm-Jorgensen CFO
28 Apr 2025 //
GLOBENEWSWIRE
AAVantgarde To Present LUCE-1, Stargardt Data At ARVO 2025
10 Mar 2025 //
GLOBENEWSWIRE
AAVantgarde To Present LUCE-1 Study At FLORetina 2024 Meeting
02 Dec 2024 //
GLOBENEWSWIRE
AAVantgarde Announces 3 Oral Presentations At ESGCT 2024 Meeting
08 Oct 2024 //
GLOBENEWSWIRE
AAVantgarde Doses First Patient In LUCE-1 Study For Retinitis Pigmentosa
16 Sep 2024 //
GLOBENEWSWIRE
AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer
09 Sep 2024 //
GLOBENEWSWIRE
AAVantgarde`s Innovative Usher 1B Clinical Study Design
03 May 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.